HRP20180943T1 - Pročišćavanje protutijela preko kromatografije kationske izmjene - Google Patents
Pročišćavanje protutijela preko kromatografije kationske izmjene Download PDFInfo
- Publication number
- HRP20180943T1 HRP20180943T1 HRP20180943TT HRP20180943T HRP20180943T1 HR P20180943 T1 HRP20180943 T1 HR P20180943T1 HR P20180943T T HRP20180943T T HR P20180943TT HR P20180943 T HRP20180943 T HR P20180943T HR P20180943 T1 HRP20180943 T1 HR P20180943T1
- Authority
- HR
- Croatia
- Prior art keywords
- mes
- nacl
- value
- cation exchange
- exchange chromatography
- Prior art date
Links
- 238000011091 antibody purification Methods 0.000 title 1
- 238000005277 cation exchange chromatography Methods 0.000 title 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 18
- 239000011780 sodium chloride Substances 0.000 claims 9
- 239000011534 wash buffer Substances 0.000 claims 6
- 239000007993 MOPS buffer Substances 0.000 claims 3
- 229960000397 bevacizumab Drugs 0.000 claims 3
- 239000012149 elution buffer Substances 0.000 claims 3
- 239000006167 equilibration buffer Substances 0.000 claims 3
- 238000000746 purification Methods 0.000 claims 3
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Claims (3)
1. Uporaba, naznačena time, da se upotrebljava
ekvilibracijski pufer koji obuhvaća 13 do 33 mM MES i 50 do 70 mM NaCl, uz vrijednost pH od 5,1 do 5,9,
prvi pufer za ispiranje koji obuhvaća 15 do 35 mM MOPS uz vrijednost pH od 6,6 do 7,4,
drugi pufer za ispiranje koji obuhvaća 13 do 33 mM MES i 5 do 20 mM NaCl, uz vrijednost pH od 5,1 do 5,9, i
eluacijski pufer koji obuhvaća 13 do 33 mM MES i 160 do 190 NaCl, uz vrijednost pH od 5,4 do 5,6,
za pročišćavanje Bevacizumaba.
2. Uporaba prema zahtjevu 1, naznačena time, da se nadalje upotrebljava
ekvilibracijski pufer koji obuhvaća 23 mM MES i 60 mM NaCl, uz vrijednost pH od 5,5 i uz provodljivost od 6,9 mS/cm,
prvi pufer za ispiranje koji obuhvaća 25 mM MOPS uz vrijednost pH od 7,0,
drugi pufer za ispiranje koji obuhvaća 23 mM MES i 10 mM NaCl, uz vrijednost pH od 5,5 i uz provodljivost od 1,5 mS/cm, i
eluacijski pufer koji obuhvaća 23 mM MES i 175 mM NaCl, uz vrijednost pH od 5,5 i uz provodljivost od 18 mS/cm,
za pročišćavanje Bevacizumaba.
3. Uporaba prema zahtjevu 1, naznačena time, da se nadalje upotrebljava
ekvilibracijski pufer koji obuhvaća 23 mM MES i 60 mM NaCl, uz vrijednost pH od 5,4 do 5,6 i uz provodljivost od 6,1 do 7,7 mS/cm,
prvi pufer za ispiranje koji obuhvaća 25 mM MOPS uz vrijednost pH od 6,9 do 7,1 i uz provodljivost od 0,2 do 1,2 mS/cm,
drugi pufer za ispiranje koji obuhvaća 23 mM MES i 10 mM NaCl, uz vrijednost pH od 5,4 do 5,6 i uz provodljivost od 1,2 do 1,8 mS/cm, i
eluacijski pufer koji obuhvaća 23 mM MES i 175 mM NaCl, uz vrijednost pH od 5,45 do 5,55 i uz provodljivost od 17,5 do 18,5 mS/cm,
za pročišćavanje Bevacizumaba.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98382507P | 2007-10-30 | 2007-10-30 | |
| EP14189095.4A EP2840090B1 (en) | 2007-10-30 | 2008-10-29 | Antibody purification by cation exchange chromatography |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20180943T1 true HRP20180943T1 (hr) | 2018-08-10 |
Family
ID=40262967
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20150282TT HRP20150282T4 (hr) | 2007-10-30 | 2015-03-12 | Purifikacija protutijela pomoću kromatografije kationskom izmjenom |
| HRP20180943TT HRP20180943T1 (hr) | 2007-10-30 | 2018-06-18 | Pročišćavanje protutijela preko kromatografije kationske izmjene |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20150282TT HRP20150282T4 (hr) | 2007-10-30 | 2015-03-12 | Purifikacija protutijela pomoću kromatografije kationskom izmjenom |
Country Status (32)
| Country | Link |
|---|---|
| US (3) | US20090148435A1 (hr) |
| EP (4) | EP2215117B2 (hr) |
| JP (5) | JP5237382B2 (hr) |
| KR (3) | KR20150008503A (hr) |
| CN (3) | CN105315323A (hr) |
| AR (2) | AR069097A1 (hr) |
| AU (1) | AU2008318865B2 (hr) |
| BR (1) | BRPI0817182A2 (hr) |
| CA (1) | CA2703279C (hr) |
| CL (1) | CL2008003218A1 (hr) |
| CO (1) | CO6280422A2 (hr) |
| CY (1) | CY1116129T1 (hr) |
| DK (3) | DK2565206T3 (hr) |
| ES (3) | ES2572958T3 (hr) |
| HK (4) | HK1182401A1 (hr) |
| HR (2) | HRP20150282T4 (hr) |
| HU (3) | HUE037409T2 (hr) |
| IL (4) | IL205310A0 (hr) |
| ME (1) | ME02101B (hr) |
| MX (1) | MX2010004740A (hr) |
| NZ (1) | NZ584839A (hr) |
| PE (1) | PE20091434A1 (hr) |
| PH (1) | PH12013501128A1 (hr) |
| PL (3) | PL2840090T3 (hr) |
| PT (1) | PT2215117E (hr) |
| RS (1) | RS53850B2 (hr) |
| RU (1) | RU2498991C2 (hr) |
| SG (2) | SG175597A1 (hr) |
| SI (3) | SI2565206T1 (hr) |
| TW (2) | TWI554517B (hr) |
| WO (1) | WO2009058812A1 (hr) |
| ZA (2) | ZA201002850B (hr) |
Families Citing this family (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101364902B1 (ko) | 2003-11-05 | 2014-02-21 | 로슈 글리카트 아게 | 증가된 ｆｃ 수용체 결합 친화성 및 효과기 기능을 가진 ｃｄ20 항체 |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| RU2438705C2 (ru) * | 2005-01-21 | 2012-01-10 | Дженентек, Инк. | Введение фиксированных доз her-антител |
| NZ590431A (en) | 2005-02-23 | 2012-08-31 | Genentech Inc | Extending time to disease progression or survival in cancer patients using a HER dimerization inhibitor |
| US8911964B2 (en) | 2006-09-13 | 2014-12-16 | Abbvie Inc. | Fed-batch method of making human anti-TNF-alpha antibody |
| NZ575328A (en) | 2006-09-13 | 2012-06-29 | Abbott Lab | Cell culture improvements |
| NZ578824A (en) | 2007-03-02 | 2012-03-30 | Genentech Inc | Predicting response to a her dimerisation inhibitor based on low her3 expression |
| RU2498991C2 (ru) | 2007-10-30 | 2013-11-20 | Дженентек, Инк. | Очистка антител с помощью катионообменной хроматографии |
| TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物 |
| BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
| AR073295A1 (es) | 2008-09-16 | 2010-10-28 | Genentech Inc | Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion. |
| US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| JP5856845B2 (ja) * | 2008-10-20 | 2016-02-10 | アッヴィ・インコーポレイテッド | 抗体精製中におけるウイルスの不活性化 |
| ES2535734T3 (es) | 2008-10-20 | 2015-05-14 | Abbvie Inc. | Aislamiento y purificación de anticuerpos mediante cromatografía de afinidad con la proteína A |
| AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
| WO2011037983A1 (en) * | 2009-09-23 | 2011-03-31 | Medarex, Inc. | Cation exchange chromatography |
| TWI426920B (zh) * | 2010-03-26 | 2014-02-21 | Hoffmann La Roche | 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體 |
| EP2552961B1 (en) | 2010-03-30 | 2017-12-20 | Janssen Biotech, Inc. | Humanized il-25 antibodies |
| WO2011143653A2 (en) | 2010-05-14 | 2011-11-17 | Oregon Health & Science University | Recombinant hcmv and rhcmv vectors and uses thereof |
| RU2594163C2 (ru) * | 2010-05-25 | 2016-08-10 | Дженентек, Инк. | Способы очистки полипептидов |
| GB201012603D0 (en) | 2010-07-27 | 2010-09-08 | Ucb Pharma Sa | Protein purification |
| CN103380144B (zh) | 2010-12-21 | 2016-03-02 | 霍夫曼-拉罗奇有限公司 | 同等型富集的抗体制备物及其获得方法 |
| DK2691411T3 (da) * | 2011-03-29 | 2020-05-11 | Glaxosmithkline Llc | Buffersystem til proteinoprensning |
| WO2012160530A1 (en) * | 2011-05-26 | 2012-11-29 | Dr. Reddy's Laboratories Limited | Purification of antibodies |
| LT2691530T (lt) | 2011-06-10 | 2018-08-10 | Oregon Health & Science University | Cmv glikoproteinai ir rekombinantiniai vektoriai |
| WO2013054250A1 (en) * | 2011-10-10 | 2013-04-18 | Dr Reddy's Laboratories Limited | Purification method |
| CN109908341B (zh) | 2011-10-14 | 2023-06-27 | 霍夫曼-拉罗奇有限公司 | Her2二聚化抑制剂帕妥珠单抗的用途和包含her2二聚化抑制剂帕妥珠单抗的制品 |
| RU2478646C1 (ru) * | 2011-11-28 | 2013-04-10 | Федеральное государственное бюджетное учреждение науки Институт молекулярной биологии им.В.А.Энгельгардта Российской академии наук (ИМБ РАН) | Способ получения высокоаффинных поликлональных антител |
| IL267585B (en) | 2011-12-22 | 2022-09-01 | Genentech Inc | Ion exchange membrane chromatography |
| HRP20211641T1 (hr) | 2012-07-13 | 2022-02-04 | Roche Glycart Ag | Bispecifična protutijela anti-vegf/anti-ang-2 i njihova primjena u liječenju vaskularnih očnih bolesti |
| WO2014034644A1 (ja) * | 2012-08-27 | 2014-03-06 | 旭化成メディカル株式会社 | 温度応答性クロマトグラフィーによる抗体の精製方法 |
| CN103217499B (zh) * | 2013-01-15 | 2015-12-02 | 珠海市丽珠单抗生物技术有限公司 | 一种测定免疫球蛋白电荷异构体的糖基化和末端修饰情况的方法 |
| WO2014137903A2 (en) | 2013-03-08 | 2014-09-12 | Genzyme Corporation | Integrated continuous manufacturing of therapeutic protein drug substances |
| UY35517A (es) * | 2013-04-04 | 2014-10-31 | Mabxience S A | Un procedimiento para aumentar la formación de ácido piroglutamico de una proteína |
| SG10201706045RA (en) | 2013-04-16 | 2017-08-30 | Genentech Inc | Pertuzumab variants and evaluation thereof |
| KR101700580B1 (ko) | 2013-10-30 | 2017-02-13 | (주)셀트리온 | 양이온 교환 크로마토그래피를 이용한 항체의 아형 분리 방법 |
| CN104628846B (zh) * | 2013-11-06 | 2019-12-06 | 三生国健药业（上海）股份有限公司 | 重组蛋白质的纯化方法 |
| CN105979963B (zh) * | 2013-11-25 | 2020-03-03 | 西雅图基因公司 | 从cho细胞培养物中制备抗体用于偶联 |
| TWI709569B (zh) | 2014-01-17 | 2020-11-11 | 美商健臻公司 | 無菌層析樹脂及其用於製造方法的用途 |
| TWI671312B (zh) | 2014-01-17 | 2019-09-11 | 美商健臻公司 | 無菌層析法及製法 |
| EP3102589A1 (en) * | 2014-02-04 | 2016-12-14 | Biogen MA Inc. | Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications |
| ES2784749T3 (es) | 2014-03-10 | 2020-09-30 | Richter Gedeon Nyrt | Purificación de inmunoglobulina con el uso de etapas de limpieza previa |
| CN105017418B (zh) * | 2014-03-27 | 2021-02-23 | 上海药明康德新药开发有限公司 | 单克隆抗体纯化工艺方法 |
| WO2015164665A1 (en) | 2014-04-25 | 2015-10-29 | Genentech, Inc. | Methods of treating early breast cancer with trastuzumab-mcc-dm1 and pertuzumab |
| JP6487026B2 (ja) | 2014-07-16 | 2019-03-20 | オレゴン ヘルス アンド サイエンス ユニバーシティ | 外来抗原を含むヒトサイトメガロウイルス |
| CN105315369B (zh) * | 2014-07-25 | 2020-03-13 | 山东博安生物技术有限公司 | 利用阳离子交换层析纯化蛋白质 |
| CN107636005B (zh) * | 2015-03-13 | 2021-07-16 | 百时美施贵宝公司 | 在色谱过程中利用碱洗涤去除杂质 |
| US11406715B2 (en) | 2015-05-30 | 2022-08-09 | Genentech, Inc. | Methods of treating HER2-positive metastatic breast cancer |
| KR101657690B1 (ko) * | 2015-06-05 | 2016-09-19 | 주식회사 녹십자홀딩스 | 혈장 유래 b형 간염 사람 면역글로불린 제제의 제조방법 |
| WO2017087280A1 (en) | 2015-11-16 | 2017-05-26 | Genentech, Inc. | Methods of treating her2-positive cancer |
| EP3377636A4 (en) | 2015-11-20 | 2019-11-06 | Oregon Health & Science University | CMV VECTORS WITH MIKRORNA DETECTION ELEMENTS |
| GB201600512D0 (en) * | 2016-01-12 | 2016-02-24 | Univ York | Recombinant protein production |
| CA3019426A1 (en) | 2016-04-15 | 2017-10-19 | The Trustees Of The University Of Pennsylvania | Compositions for treatment of wet age-related macular degeneration |
| EP3454903A4 (en) * | 2016-05-13 | 2020-08-19 | Askgene Pharma, Inc. | NEW ANGIOPOIETIN-2, VEGF DUAL ANTAGONISTS |
| WO2018011381A1 (en) * | 2016-07-15 | 2018-01-18 | F. Hoffmann-La Roche Ag | Method for purifying pegylated erythropoietin |
| CN106222222B (zh) * | 2016-08-08 | 2019-10-29 | 湖北医药学院 | 一种重组人白血病抑制因子的制备方法 |
| WO2018045587A1 (zh) * | 2016-09-12 | 2018-03-15 | 广东东阳光药业有限公司 | 一种抗vegf类单克隆抗体的纯化方法 |
| CN106380519B (zh) * | 2016-10-17 | 2019-11-01 | 深圳万乐药业有限公司 | 一种单克隆抗体的纯化方法 |
| EA201990937A1 (ru) | 2016-10-18 | 2019-09-30 | Орегон Хелс Энд Сайенс Юниверсити | Цитомегаловирусные векторы, выбирающие t-клетки, ограниченные по молекулам главного комплекса гистосовместимости e |
| EP3532498A1 (en) * | 2016-10-31 | 2019-09-04 | Hexal AG | Antibody preparation |
| EP3562844A1 (en) | 2016-12-28 | 2019-11-06 | Genentech, Inc. | Treatment of advanced her2 expressing cancer |
| CN115089704A (zh) | 2017-01-17 | 2022-09-23 | 基因泰克公司 | 皮下her2抗体配制剂 |
| HRP20240069T1 (hr) | 2017-03-02 | 2024-03-29 | Genentech, Inc. | Adjuvantno liječenje her2-pozitivnog raka dojke |
| BE1025090B1 (fr) * | 2017-03-30 | 2018-10-29 | Univercells Sa | Procede et kit de purification de proteines |
| WO2018190677A2 (en) * | 2017-04-14 | 2018-10-18 | Cj Healthcare Corporation | Method for purifying analogous antibody using cation-exchange chromatography |
| TW201902509A (zh) | 2017-04-24 | 2019-01-16 | 美商建南德克公司 | Erbb2/her2突變 |
| WO2018237159A1 (en) * | 2017-06-21 | 2018-12-27 | Cephalon, Inc. | WASH PAD FOR CATIONIC EXCHANGE CHROMATOGRAPHY |
| TWI826393B (zh) * | 2017-09-22 | 2023-12-21 | 美商免疫遺傳股份有限公司 | 使用陽離子交換層析法分離三輕鏈抗體 |
| CN110272491B (zh) * | 2018-03-13 | 2023-01-24 | 江苏恒瑞医药股份有限公司 | 一种抗pd-1抗体的纯化工艺 |
| CN112313248A (zh) * | 2018-03-29 | 2021-02-02 | 百时美施贵宝公司 | 纯化单体单克隆抗体的方法 |
| WO2019217570A1 (en) * | 2018-05-08 | 2019-11-14 | Waters Technologies Corporation | Methods, compositions and kits useful for ph gradient cation exchange chromatography |
| SG11202101860UA (en) | 2018-08-31 | 2021-03-30 | Genzyme Corp | Sterile chromatography resin and use thereof in manufacturing processes |
| EP3643322A1 (en) * | 2018-10-26 | 2020-04-29 | Mabion SA | Low aggregate anti cd20 ligand formulation |
| CN109320611B (zh) * | 2018-10-31 | 2022-06-03 | 鼎康(武汉)生物医药有限公司 | 一种人鼠嵌合单克隆抗体生物类似药的纯化方法 |
| CN112206327A (zh) * | 2019-07-12 | 2021-01-12 | 上海药明生物技术有限公司 | 一种抗体偶联药物的制备及其高通量筛选方法 |
| KR20220079844A (ko) * | 2019-10-14 | 2022-06-14 | 피어스 바이오테크놀로지, 인크 | 펩티드 정제 제제 및 방법 |
| BR112022010069A2 (pt) * | 2019-11-25 | 2022-09-06 | Akeso Biopharma Inc | Anticorpo biespecífico, molécula de ácido nucleico isolada, vetor, célula hospedeira, conjugado, kit, uso do anticorpo biespecífico e composição farmacêutica |
| KR102153258B1 (ko) * | 2020-02-21 | 2020-09-07 | 프레스티지바이오로직스 주식회사 | 베바시주맙 정제의 최적화된 방법 |
| US11416468B2 (en) * | 2020-07-21 | 2022-08-16 | International Business Machines Corporation | Active-active system index management |
| CN114591438B (zh) * | 2022-04-25 | 2023-12-05 | 达石药业(广东)有限公司 | 一种采用阳离子交换层析法纯化双特异性抗体的方法 |
| CN115850493B (zh) * | 2022-11-08 | 2024-03-12 | 江苏耀海生物制药有限公司 | 一种二价纳米抗体Cablivi的分离纯化方法 |
Family Cites Families (109)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
| US4515893A (en) | 1979-04-26 | 1985-05-07 | Ortho Pharmaceutical Corporation | Hybrid cell line for producing complement-fixing monoclonal antibody to human T cells |
| GB2070818A (en) | 1980-02-04 | 1981-09-09 | Philips Electronic Associated | Regulated power supply for an image intensifier |
| WO1984002129A1 (en) | 1982-11-22 | 1984-06-07 | Takeda Chemical Industries Ltd | Human immune interferon protein and process for its preparation |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| US6054561A (en) * | 1984-02-08 | 2000-04-25 | Chiron Corporation | Antigen-binding sites of antibody molecules specific for cancer antigens |
| US4753894A (en) | 1984-02-08 | 1988-06-28 | Cetus Corporation | Monoclonal anti-human breast cancer antibodies |
| US5169774A (en) * | 1984-02-08 | 1992-12-08 | Cetus Oncology Corporation | Monoclonal anti-human breast cancer antibodies |
| WO1986002068A1 (en) * | 1984-09-26 | 1986-04-10 | Takeda Chemical Industries, Ltd. | Mutual separation of proteins |
| US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| US5196323A (en) | 1985-04-27 | 1993-03-23 | Boehringer Ingelheim International Gmbh | Process for preparing and purifying alpha-interferon |
| GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
| US5525338A (en) * | 1992-08-21 | 1996-06-11 | Immunomedics, Inc. | Detection and therapy of lesions with biotin/avidin conjugates |
| US5091178A (en) | 1986-02-21 | 1992-02-25 | Oncogen | Tumor therapy with biologically active anti-tumor antibodies |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
| CA1283072C (en) | 1986-12-01 | 1991-04-16 | Timothy Durance | Process for the isolation and separation of lysozyme and avidin from eggwhite |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US5451662A (en) | 1987-10-23 | 1995-09-19 | Schering Corporation | Method of purifying protein |
| US5118796A (en) | 1987-12-09 | 1992-06-02 | Centocor, Incorporated | Efficient large-scale purification of immunoglobulins and derivatives |
| US5091313A (en) | 1988-08-05 | 1992-02-25 | Tanox Biosystems, Inc. | Antigenic epitopes of IgE present on B cell but not basophil surface |
| WO1989006692A1 (en) * | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
| US5720937A (en) | 1988-01-12 | 1998-02-24 | Genentech, Inc. | In vivo tumor detection assay |
| IT1219874B (it) | 1988-03-18 | 1990-05-24 | Fidia Farmaceutici | Utilizzazione del fattore di crescita nervoso umano e sue composizioni farmaceutiche |
| US5115101A (en) * | 1988-06-08 | 1992-05-19 | Miles Inc. | Removal of protein A from antibody preparations |
| DE68919361T2 (de) | 1988-06-21 | 1995-05-24 | Genentech Inc | Therapeutische zusammensetzungen für die behandlung von myocard-infarkten. |
| DE68925971T2 (de) | 1988-09-23 | 1996-09-05 | Cetus Oncology Corp | Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5112951A (en) * | 1989-07-28 | 1992-05-12 | Hybritech Incorporated | Separation of anti-metal chelate antibodies |
| US5110913A (en) * | 1990-05-25 | 1992-05-05 | Miles Inc. | Antibody purification method |
| EP0467466A1 (en) * | 1990-07-16 | 1992-01-22 | Eastman Kodak Company | Method for the purification of immunoreactive labeled thyroxine conjugates |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| WO1992022653A1 (en) | 1991-06-14 | 1992-12-23 | Genentech, Inc. | Method for making humanized antibodies |
| DE69232944T2 (de) | 1991-08-14 | 2003-12-24 | Genentech Inc | Veränderte Immunglobuline für spezifische FC-Epsilon Rezeptoren |
| EP0604580A1 (en) | 1991-09-19 | 1994-07-06 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES |
| JPH07501451A (ja) | 1991-11-25 | 1995-02-16 | エンゾン・インコーポレイテッド | 多価抗原結合タンパク質 |
| JPH05202098A (ja) | 1992-01-29 | 1993-08-10 | Snow Brand Milk Prod Co Ltd | 乳質原料から生理活性物質の製造法 |
| CA2129663C (en) | 1992-02-06 | 2005-07-05 | James S. Huston | Biosynthetic binding protein for cancer marker |
| US5279823A (en) | 1992-06-08 | 1994-01-18 | Genentech, Inc. | Purified forms of DNASE |
| ATE161192T1 (de) | 1992-08-21 | 1998-01-15 | Genentech Inc | Verfahren zur behandlung einer durch lfa-1 vermittelten störung |
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| PL174721B1 (pl) | 1992-11-13 | 1998-09-30 | Idec Pharma Corp | Przeciwciało monoklonalne anty-CD20 |
| US5595721A (en) | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
| ATE157455T1 (de) | 1993-12-10 | 1997-09-15 | Genentech Inc | Methoden zur diagnose von allergie und prüfung anti-allergischer therapeutika |
| ATE164079T1 (de) | 1994-01-18 | 1998-04-15 | Genentech Inc | Verfahren zur behandlung von parasitären infektionen unter verwendung von ige-antagonisten |
| US5429746A (en) * | 1994-02-22 | 1995-07-04 | Smith Kline Beecham Corporation | Antibody purification |
| US5686070A (en) | 1994-03-03 | 1997-11-11 | Genentech, Inc. | Methods for treating bacterial pneumonia |
| US5534615A (en) | 1994-04-25 | 1996-07-09 | Genentech, Inc. | Cardiac hypertrophy factor and uses therefor |
| IL117645A (en) | 1995-03-30 | 2005-08-31 | Genentech Inc | Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| CA2222231A1 (en) | 1995-06-07 | 1996-12-19 | Imclone Systems Incorporated | Antibody and antibody fragments for inhibiting the growth of tumors |
| US5714583A (en) | 1995-06-07 | 1998-02-03 | Genetics Institute, Inc. | Factor IX purification methods |
| US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| DE69714966T2 (de) | 1996-01-23 | 2003-04-24 | Genentech Inc | Antikörper gegen cd 18 zur verwendung gegen gehirnschlag |
| US7147851B1 (en) | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
| PL191400B1 (pl) | 1996-11-15 | 2006-05-31 | Genentech Inc | Sposób izolowania neurotrofiny z mieszaniny białek i kompozycja neurotrofiny |
| ES2293661T3 (es) | 1996-11-27 | 2008-03-16 | Genentech, Inc. | Purificacion por afinidad de polipeptido en una matriz de proteinas a. |
| CA2272842C (en) | 1996-11-27 | 2012-05-15 | Genentech, Inc. | Humanized anti-cd11a antibodies |
| ES2236634T3 (es) | 1997-04-07 | 2005-07-16 | Genentech, Inc. | Anticuerpos anti-vegf. |
| EP2301580B1 (en) | 1997-04-07 | 2012-01-18 | Genentech, Inc. | Container holding anti-VEGF antibodies |
| US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| EP0981618B2 (en) | 1997-05-15 | 2011-08-24 | Genentech, Inc. | Anti-apo-2 antibody |
| US5994511A (en) | 1997-07-02 | 1999-11-30 | Genentech, Inc. | Anti-IgE antibodies and methods of improving polypeptides |
| KR101036414B1 (ko) * | 1998-05-06 | 2011-05-23 | 제넨테크, 인크. | 이온 교환 크로마토그래피에 의한 단백질 정제 방법 |
| IL139609A (en) | 1998-06-01 | 2006-06-11 | Genentech Inc | Separation of polypeptides monomers |
| HU228076B1 (en) | 1998-06-09 | 2012-10-29 | Csl Behring Ag | Process for producing immunoglobulins for intravenous administration and other immunoglobulin products |
| AU784045B2 (en) | 1999-06-25 | 2006-01-19 | Genentech Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| NZ518477A (en) | 1999-10-29 | 2004-10-29 | Genentech Inc | Isolated anti-prostate stem cell antigen (PSCA) antibodies that internalise upon binding to PSCA on a mammalian cell, including a PSCA-expressing tumour cell, in vivo |
| UA83458C2 (uk) | 2000-09-18 | 2008-07-25 | Байоджен Айдек Ма Інк. | Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf) |
| US6417355B1 (en) | 2001-04-11 | 2002-07-09 | The United States Of America As Represented By The Secretary Of The Navy | Geminal-dinitro-1-5 diazocine derivatives |
| GB0113179D0 (en) * | 2001-05-31 | 2001-07-25 | Novartis Ag | Organic compounds |
| US7321026B2 (en) | 2001-06-27 | 2008-01-22 | Skytech Technology Limited | Framework-patched immunoglobulins |
| US6770027B2 (en) * | 2001-10-05 | 2004-08-03 | Scimed Life Systems, Inc. | Robotic endoscope with wireless interface |
| AU2002351495A1 (en) | 2001-10-17 | 2003-04-28 | Human Genome Sciences, Inc. | Neutrokine-alpha and neutrokine-alpha splice variant |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| AU2003208415B2 (en) | 2002-02-14 | 2009-05-28 | Immunomedics, Inc. | Anti-CD20 antibodies and fusion proteins thereof and methods of use |
| CA2490423A1 (en) * | 2002-06-21 | 2003-12-31 | Biogen Idec Inc. | Buffered formulations for concentrating antibodies and methods of use thereof |
| PT1543038T (pt) * | 2002-09-11 | 2017-07-07 | Genentech Inc | Purificação de proteína |
| EA021644B1 (ru) | 2002-10-17 | 2015-08-31 | Генмаб А/С | Человеческое моноклональное антитело против cd20 и его применение |
| EP1569690B1 (en) | 2002-12-13 | 2011-07-27 | Mitra Medical Technology AB | Antilymphoma targeting agents with effector and affinity functions linked by a trifunctional reagent |
| DK1572744T3 (da) | 2002-12-16 | 2010-09-20 | Genentech Inc | Immunoglobulinvarianter og deres anvendelser |
| KR20050094832A (ko) | 2002-12-31 | 2005-09-28 | 알투스 파마슈티컬스 인코포레이티드 | 단백질 결정과 이온성 중합체를 함유하는 복합체 |
| JPWO2004087761A1 (ja) * | 2003-03-31 | 2006-07-27 | 麒麟麦酒株式会社 | ヒトモノクローナル抗体およびヒトポリクローナル抗体の精製 |
| CA2525251C (en) | 2003-05-09 | 2015-10-27 | Duke University | Cd20-specific antibodies and methods employing same |
| AR044388A1 (es) | 2003-05-20 | 2005-09-07 | Applied Molecular Evolution | Moleculas de union a cd20 |
| US20050079184A1 (en) | 2003-08-08 | 2005-04-14 | Immunomedics, Inc. | Bispecific antibodies for inducing apoptosis of tumor and diseased cells |
| US8147832B2 (en) | 2003-08-14 | 2012-04-03 | Merck Patent Gmbh | CD20-binding polypeptide compositions and methods |
| KR100524074B1 (ko) | 2003-10-01 | 2005-10-26 | 삼성전자주식회사 | 베젤 구조를 가지는 전자기기 |
| TW200533357A (en) * | 2004-01-08 | 2005-10-16 | Millennium Pharm Inc | 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases |
| US20060002930A1 (en) * | 2004-04-16 | 2006-01-05 | Genentech, Inc. | Treatment of disorders |
| CN101022829A (zh) * | 2004-04-16 | 2007-08-22 | 健泰科生物技术公司 | 用抗cd20抗体治疗多软骨炎和多发性单神经炎 |
| RU2441071C2 (ru) * | 2004-12-22 | 2012-01-27 | Дженентек, Инк. | Способы получения растворимых многопроходных трансмембранных белков |
| ES2797480T3 (es) * | 2005-03-11 | 2020-12-02 | Wyeth Llc | Un procedimiento de cromatografía de reparto débil |
| AU2006261185B2 (en) * | 2005-06-17 | 2012-02-16 | Janssen Alzheimer Immunotherapy | Methods of purifying anti A beta antibodies |
| WO2007028154A2 (en) * | 2005-09-02 | 2007-03-08 | Northwestern University | Encapsulated arsenic drugs |
| KR20080111487A (ko) * | 2006-03-20 | 2008-12-23 | 메다렉스, 인코포레이티드 | 단백질 정제 방법 |
| KR20090005315A (ko) * | 2006-04-05 | 2009-01-13 | 애보트 바이오테크놀로지 리미티드 | 항체 정제 |
| ES2755386T5 (es) * | 2006-08-28 | 2023-04-05 | Ares Trading Sa | Proceso para la purificación de proteínas que contienen fragmentos Fc |
| US8620738B2 (en) | 2006-08-31 | 2013-12-31 | Visa U.S.A. Inc | Loyalty program incentive determination |
| CA2682292A1 (en) * | 2007-03-30 | 2008-10-09 | Medimmune, Llc | Aqueous formulation comprising an anti-human interferon alpha antibody |
| RU2498991C2 (ru) | 2007-10-30 | 2013-11-20 | Дженентек, Инк. | Очистка антител с помощью катионообменной хроматографии |
| WO2015198451A1 (ja) | 2014-06-26 | 2015-12-30 | 楽天株式会社 | 情報処理装置、情報処理方法及び情報処理プログラム |
-
2008
- 2008-10-29 RU RU2010121816/10A patent/RU2498991C2/ru active
- 2008-10-29 EP EP08844379.1A patent/EP2215117B2/en active Active
- 2008-10-29 SI SI200831634A patent/SI2565206T1/sl unknown
- 2008-10-29 PL PL14189095T patent/PL2840090T3/pl unknown
- 2008-10-29 DK DK12189190.7T patent/DK2565206T3/en active
- 2008-10-29 SG SG2011073087A patent/SG175597A1/en unknown
- 2008-10-29 WO PCT/US2008/081516 patent/WO2009058812A1/en active Application Filing
- 2008-10-29 BR BRPI0817182 patent/BRPI0817182A2/pt not_active Application Discontinuation
- 2008-10-29 PL PL08844379T patent/PL2215117T5/pl unknown
- 2008-10-29 ME MEP-2015-34A patent/ME02101B/me unknown
- 2008-10-29 SI SI200831381T patent/SI2215117T2/en unknown
- 2008-10-29 NZ NZ584839A patent/NZ584839A/en unknown
- 2008-10-29 MX MX2010004740A patent/MX2010004740A/es active IP Right Grant
- 2008-10-29 EP EP18151178.3A patent/EP3441402A1/en not_active Withdrawn
- 2008-10-29 CN CN201510941252.9A patent/CN105315323A/zh active Pending
- 2008-10-29 US US12/260,623 patent/US20090148435A1/en not_active Abandoned
- 2008-10-29 CA CA2703279A patent/CA2703279C/en active Active
- 2008-10-29 JP JP2010532193A patent/JP5237382B2/ja active Active
- 2008-10-29 ES ES12189190.7T patent/ES2572958T3/es active Active
- 2008-10-29 SG SG10201401690XA patent/SG10201401690XA/en unknown
- 2008-10-29 TW TW103117553A patent/TWI554517B/zh active
- 2008-10-29 KR KR1020147036127A patent/KR20150008503A/ko not_active Application Discontinuation
- 2008-10-29 EP EP14189095.4A patent/EP2840090B1/en active Active
- 2008-10-29 HU HUE14189095A patent/HUE037409T2/hu unknown
- 2008-10-29 DK DK14189095.4T patent/DK2840090T3/en active
- 2008-10-29 AR ARP080104725A patent/AR069097A1/es active IP Right Grant
- 2008-10-29 RS RS20150156A patent/RS53850B2/sr unknown
- 2008-10-29 PE PE2008001848A patent/PE20091434A1/es active IP Right Grant
- 2008-10-29 CN CN200880119331XA patent/CN101889025B/zh active Active
- 2008-10-29 KR KR1020127028627A patent/KR20140015166A/ko not_active Application Discontinuation
- 2008-10-29 AU AU2008318865A patent/AU2008318865B2/en active Active
- 2008-10-29 EP EP12189190.7A patent/EP2565206B1/en active Active
- 2008-10-29 ES ES14189095.4T patent/ES2666170T3/es active Active
- 2008-10-29 TW TW097141614A patent/TWI448330B/zh active
- 2008-10-29 HU HUE12189190A patent/HUE027668T2/en unknown
- 2008-10-29 PL PL12189190T patent/PL2565206T3/pl unknown
- 2008-10-29 ES ES08844379.1T patent/ES2533266T5/es active Active
- 2008-10-29 PT PT88443791T patent/PT2215117E/pt unknown
- 2008-10-29 CN CN201310495290.7A patent/CN103554215B/zh active Active
- 2008-10-29 SI SI200831945T patent/SI2840090T1/en unknown
- 2008-10-29 KR KR1020107011765A patent/KR101241486B1/ko active IP Right Grant
- 2008-10-29 DK DK08844379.1T patent/DK2215117T4/en active
- 2008-10-29 HU HUE08844379A patent/HUE024877T2/en unknown
- 2008-10-29 CL CL2008003218A patent/CL2008003218A1/es unknown
-
2010
- 2010-04-22 ZA ZA2010/02850A patent/ZA201002850B/en unknown
- 2010-04-25 IL IL205310A patent/IL205310A0/en unknown
- 2010-05-21 CO CO10061141A patent/CO6280422A2/es active IP Right Grant
- 2010-10-28 HK HK13109765.9A patent/HK1182401A1/zh unknown
- 2010-10-28 HK HK10110121.9A patent/HK1143821A1/xx active IP Right Maintenance
-
2011
- 2011-03-23 ZA ZA2011/02169A patent/ZA201102169B/en unknown
-
2013
- 2013-03-21 JP JP2013059102A patent/JP2013173747A/ja not_active Withdrawn
- 2013-06-03 PH PH12013501128A patent/PH12013501128A1/en unknown
-
2014
- 2014-09-30 IL IL234901A patent/IL234901A0/en unknown
- 2014-09-30 IL IL234902A patent/IL234902A0/en unknown
- 2014-11-03 US US14/531,880 patent/US9896478B2/en active Active
-
2015
- 2015-02-19 JP JP2015030881A patent/JP2015155406A/ja not_active Withdrawn
- 2015-02-19 JP JP2015030880A patent/JP5885864B2/ja active Active
- 2015-03-12 HR HRP20150282TT patent/HRP20150282T4/hr unknown
- 2015-03-19 CY CY20151100275T patent/CY1116129T1/el unknown
- 2015-06-18 IL IL239495A patent/IL239495B/en not_active IP Right Cessation
- 2015-07-28 HK HK15107237.1A patent/HK1206753A1/xx unknown
-
2016
- 2016-07-12 JP JP2016137986A patent/JP2017019790A/ja active Pending
- 2016-08-08 HK HK16109407.0A patent/HK1221234A1/zh unknown
-
2017
- 2017-12-21 US US15/850,885 patent/US20180118781A1/en not_active Abandoned
-
2018
- 2018-03-09 AR ARP180100555A patent/AR111171A2/es unknown
- 2018-06-18 HR HRP20180943TT patent/HRP20180943T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20180943T1 (hr) | Pročišćavanje protutijela preko kromatografije kationske izmjene | |
| IL197053A0 (en) | Arginine wash in protein purification using affinity chromatography | |
| UA99262C2 (uk) | СПОСІБ ЗМЕНШЕННЯ КОНЦЕНТРАЦІЇ ВІЛЬНИХ Fc-ЧАСТИН В РІДИНІ, ЩО МІСТИТЬ Fc-ВМІСНИЙ БІЛОК | |
| CL2012001710A1 (es) | Anticuerpo aislado que se enlaza selectivamente a hepcidina-25 humana y cuyas hcvr y lcvr tienen las secuencias de aminoácido sec id nos:150 y 124; polinucleótido, vector; célula hospedadora; uso en el tratamiento y/o prevención de anemia; procedimiento de producción y composición farmacéutica (div. de sol. 3190-08). | |
| BRPI0615026A8 (pt) | imunoglobulina de domínio variável duplo e seus usos | |
| CL2008000947A1 (es) | Uso de un antagonista de la proteina beta-klotho (klb) para tratar trastornos asociados a la expresion o actividad de klb. | |
| IL204658A (en) | Pharmaceutical preparation for topical use in the form of an opaque gel-gel containing diclofenac diethylammonium salt | |
| DE602006016400D1 (de) | Damit | |
| BRPI0822895A2 (pt) | Composição efervescente, bebida para uso no tratamento de hidratação de um animal, usos de uma composição efervescente e de um agente e efervescente, e, métodos para tratar um animal com necessidade de hidratação, para estimulação um animal a beber, para fonrecer um ingrediente micronutriente ou funcional à água potável para animal, e para realçar o sabor de um elemento palatável na água potável na água para animal. | |
| BRPI0911684A2 (pt) | "composição para uso em purificação de água para uso doméstico , e , processo para purificação de água para uso doméstico | |
| GR20070100787A (el) | Υγρο μαγειρικο αλατι. | |
| DE502007001083D1 (de) | Sanitäre wasserleitungsarmatur mit strahlregler | |
| DE602005002552D1 (de) | Massagevorrichtung für Stühle oder Liegemöbel | |
| Osborne et al. | The response of Northern Hemisphere mid-latitude precipitation to aerosol forcing | |
| FR2885298B1 (fr) | Compositions cosmetiques destinees a une application topique comprenant du stearyl fumarate de sodium. | |
| TW200742764A (en) | Soap | |
| Guo | Why the Real Economy Is More “Hollowing-out”? | |
| TH89648S (th) | ที่นั่ง | |
| TH37063S1 (th) | เก้าอี้นอน | |
| TH109568S (th) | เครื่องทำน้ำอุ่น | |
| TH32862S1 (th) | ที่นั่ง | |
| TH103828S (th) | ก๊อกน้ำ | |
| TH26299S1 (th) | เก้าอี้ยาว | |
| TH81289B (th) | อุปกรณ์ข้อต่อท่อ | |
| UA11771S (uk) | Водонагрівач проточний |